Search Results
Apr 09, 2026, 03:53 ET Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
The synthetic biology market is being shaped by the growing use of engineered organisms in drug development, vaccine production, and gene therapies. The ability to manipulate DNA and create customized biological pathways is enabling breakthroughs in precision medicine and biopharmaceutical
More news about: Mordor Intelligence Private Limited
Apr 08, 2026, 13:30 ET 3D Rendering Service Market to Reach USD 7.2 Billion by 2033 Driven by Expanding Adoption Across Architecture, Real Estate, Gaming, and Product Visualization Industries: Market Research Intellect
II (Biologics and Monoclonal Antibodies), Type III (Cell and Gene Therapies), Type IV (Vaccines and Immune Modulators), Type V (RNA‑Based Therapeutics)), By Application (Oncology Treatment Channels, Rare Disease Therapeutics, Cell and Gene Therapy Platforms, Respiratory and Immunology Applications, Neuromuscular
More news about: Market Research Intellect
Apr 08, 2026, 10:30 ET Primrose Bio Function Generator™ Combinatorial Genetic Technology Case Study Published in PNAS
Generator™, a patented technology that combines protein-coding sequences across an entire genome to create large libraries of gene fusions. In a proof-of-concept study, 20 million unique gene combinations from more than 5,000 Saccharomyces cerevisiae (budding yeast) protein-coding sequences were screened,
More news about: Primrose Bio
Apr 08, 2026, 02:08 ET ATLATL Announces Agreement with Daiichi Sankyo to Deepen APAC Biotech Innovation
evaluation. ATLATL also supports key applications such as large molecule, small molecule, nucleic acid drugs, gene and cell therapy, drug delivery, as well as cutting-edge fields like multi-omics, gene editing, organoids, and organ-on-a-chip. Additionally, ATLATL provides an outstanding experimental environment
More news about: ATLATL
Apr 08, 2026, 01:00 ET RoosterBio and MineBio Life Sciences Partner to Expand Access to Scalable, High Quality MSC and Exosome Bioprocessing Solutions in China
Partnership Delivers RoosterBio's Research-Grade and CliniControl™ cGMP Media Platforms to China's Leading Cell and Gene Therapy Developers; MineBio Holds Import Approval for Immediate Order FulfillmentFREDERICK, Md., April
More news about: RoosterBio, Inc.
Apr 08, 2026, 01:00 ET The Boys & Girls Clubs of Greater Oxnard and Port Hueneme Announce Ribbon Cutting for New Premier America Boys & Girls Club
93041.This $3 million renovation marks the culmination of a bold vision made possible through the Believe in Our Next Generation campaign, the Gene Haas Foundation, and the extraordinary support of the
More news about: The Boys & Girls Clubs of Greater Oxnard and Port Hueneme (BGCOP)
Apr 07, 2026, 16:01 ET Insmed Provides Clinical Update on Phase 2b CEDAR Study
therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Apr 07, 2026, 12:10 ET QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Apr 07, 2026, 09:44 ET GREENLAND MINES APPOINTS DR. JAKOB KLØVE KEIDING AS CHIEF GEOLOGIST TO LEAD NEXT PHASE AT SKAERGAARD
of the Skaergaard Project in Southeast Greenland, one of the largest undeveloped palladium, gold, and platinum deposits in the world; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS. The Company holds, through its recent acquisition of Greenland Mines Corp., an 80%
More news about: Greenland Mines Ltd
Apr 07, 2026, 09:06 ET NCCN Announces First Fellows for New Advocacy Academy to Help Drive Effective Cancer Policy
TherapiesAlaa Ali, MD, Moffitt Cancer CenterAdvocating for a National Strategy to Protect the Cellular and Gene Therapy Pipeline: Strengthening Government, Academic, and Industry Collaboration from Bench to BedsideAlexis
More news about: National Comprehensive Cancer Network
Apr 07, 2026, 09:00 ET RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm
Apr 07, 2026, 08:19 ET Fotophase Launches to Bring Photography into the Neuroarts Movement
medicine, and creative leadership: James Rice, a photographer whose personal journey back to the camera after decades of loss helped inspire the initiative; Gene Beyt, MD, a physician, educator, and longtime photographer with expertise in human-centered design and aesthetic experience; David Butow, an internationally
More news about: Fotophase
Apr 07, 2026, 08:15 ET Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution
multimedia:https://www.prnewswire.com/news-releases/azenta-life-sciences-announces-leadership-transition-to-accelerate-gene-synthesis-strategy-and-multiomics-execution-302735494.htmlSOURCE
More news about: Azenta
Apr 07, 2026, 08:00 ET Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
speakers include key researchers and medical experts, including Dr. Makoto Kuro-o, the physician-scientist widely recognized for discovering the Klotho gene."We look forward to sharing the latest data from Klothonova's progress in α-Klotho production from encapsulated cells at this prestigious forum,"
More news about: Avai Bio, Inc.
Apr 07, 2026, 07:30 ET Allucent Expands Strategic Leadership to Advance Centers of Expertise and Fortify Specialty CRO Position
cardiometabolic diseases, and immunology & inflammation. Allucent also announced a head of advanced therapeutics spanning rare disease and cell and gene therapy (CGT) programs.
More news about: Allucent
Apr 06, 2026, 19:30 ET The Inner Circle acknowledges, Melvin Colón as a Pinnacle Professional Member Inner Circle of Excellence
to market.Mr. Colón is a licensed chemist with a proven track record of success across the pharmaceutical, biotechnology, including cell and gene therapy, biosimilars, and medical device industries, including combination products. His expertise includes Quality Assurance, Quality Control, Quality
More news about: The Inner Circle
Apr 06, 2026, 14:56 ET TGH Cancer Institute and USF Health Morsani College of Medicine Convene International Scientific Leaders for the "Microbes, Genes & Cancer" Symposium
populations. Researchers examined hepatitis-related liver cancer and examined how chronic viral infection, inflammation and altered gene pathways contribute to hepatocellular carcinoma, indicating potential opportunities for earlier detection and more targeted intervention. Sessions
More news about: Tampa General Hospital
Apr 06, 2026, 13:10 ET Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines
sign off on. The FDA accelerated the timeline in early 2026 by formalizing flexible manufacturing and quality control oversight for cell and gene therapies, clearing a path that had stalled the jump from clinical validation to commercial product[2]. Five companies have already crossed
More news about: USA News Group
Apr 06, 2026, 08:00 ET PIONEERING BRITISH BRAND, LYMA, ANNOUNCES FURTHER US EXPANSION
peer-reviewed evidence of multi-gene longevity activation from a consumer device.Key science headlines include:45 genes activated by LYMA Laser vs. 1 gene by LED, in RNA sequencing analysis6x increase in SIRT1 — the longevity gene — expression32x
More news about: LYMA
Apr 06, 2026, 07:30 ET Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant
More news about: Actinium Pharmaceuticals, Inc.
Apr 06, 2026, 07:00 ET Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Bhatnagar, M.D., Chairman and Chief Executive Officer of Soleno.PWS is a rare genetic neurodevelopmental disorder caused by an abnormality in gene expression on chromosome 15 that affects about 10,000 patients in the United States. The disease is characterized by neurological, behavioral, and metabolic
More news about: Neurocrine Biosciences, Inc.
Apr 05, 2026, 13:23 ET QURE INVESTOR NOTICE: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism, Lawsuit Filed; April 13 Deadline Nears
CNBC, and CNN reported on a call with reporters where an FDA official lashed out at uniQure.The official reportedly called uniQure's lead gene therapy candidate, AMT-130, a "failed therapy," alleging that the company is "performing a distorted or manipulated comparison in the
More news about: Hagens Berman Sobol Shapiro LLP
Apr 04, 2026, 07:56 ET RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Apr 03, 2026, 16:31 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 03, 2026, 15:19 ET REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights
REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States.
More news about: Robbins LLP